NASDAQ · ERAS
Erasca, Inc.
$14.98-$0.14 (-0.93%)
Erasca, Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.3% below the high.
Loading market information…
NASDAQ · AVXL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Anavex Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Anavex Life Sciences Corp.’s next earnings report is currently expected on Nov 24, 2026, with estimated earnings per share of -$0.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Anavex Life Sciences Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q1 2025 | Feb 12, 2025 | -$0.14+17.65% vs estimate | $0.00 |
|---|
| Q4 2024 | Dec 23, 2024 | -$0.14+12.5% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.98-$0.14 (-0.93%)
Erasca, Inc.’s quoted price sits in the upper half of its reported 52-week range, 38.3% below the high.
$54.54+$0.38 (+0.7%)
MBX Biosciences, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 24.92% below the high.
$12.10+$0.22 (+1.85%)
Absci Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.55% below the high.
$12.57+$0.26 (+2.11%)
MoonLake Immunotherapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.03% below the high.
$9.71-$0.05 (-0.46%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
$12.58$0.00 (0.0%)
Astria Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.34% below the high.
$5.71-$0.03 (-0.52%)
Valneva SE’s quoted price sits in the lower half of its reported 52-week range, 53.12% below the high.
$7.90+$0.30 (+3.95%)
Arvinas, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.55% below the high.
